Tower Research Capital LLC (Trc) Arcutis Biotherapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.39 Billion
- Q3 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 4,736 shares of ARQT stock, worth $118,400. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,736
Previous 12,414
61.85%
Holding current value
$118,400
Previous $174,000
48.85%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding ARQT
# of Institutions
252Shares Held
127MCall Options Held
404KPut Options Held
133K-
Jennison Associates LLC12.3MShares$306 Million0.14% of portfolio
-
Rubric Capital Management LP New York, NY10.7MShares$269 Million3.33% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.5MShares$262 Million5.93% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.87MShares$247 Million7.87% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$216 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $1.5B
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...